logo
Share SHARE
FONT-SIZE Plus   Neg

European Commission Gives Green Light To Bayer HealthCare's Flexyess

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said the European Commission has issued its go ahead for the approval of the company's subgroup Bayer HealthCare's new low-dose combined oral contraceptive Flexyess. Based on the European Commission's positive decision, the Health Authorities of the EU Member States will grant national approvals in the coming weeks.

Flexyess will be the first low-dose combined oral contraceptive approved in the EU member states for a flexible extended regimen, offering women the option of 'personal period planning', meaning they can choose both the number and timing of their periods according to their needs.

Dr. Flemming Ornskov, chief marketing officer at Bayer HealthCare's Pharmaceuticals division, said, "Once Flexyess is launched, women will have the convenience and flexibility to influence the timing of their periods according to their individual needs."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks baristas are now free to express their personal style at work under a new dress code announced by the world's largest specialty coffee retailer. Instead of the familiar solid black, white and khaki clothing underneath their iconic green aprons, baristas can now come for work in a range of colors and outfits that reflect their own personal tastes. Fast food giant McDonald's Corp. on Tuesday reported a 9 percent decline in profit for the second quarter from last year, reflecting one-time charges and lower sales. Earnings per share for the quarter missed analysts' expectations. Fast food giant McDonald's Corp. on Tuesday reported a 9 percent decline in profit for the second quarter from last year, reflecting one-time charges and lower sales. Earnings per share for the quarter missed analysts' expectations.
comments powered by Disqus
Follow RTT